deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT04616924

RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease (CleaR-MAC)

Study of RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex (MAC) Disease in Adults With Nodular Bronchiectasis (CleaR-MAC Trial)

Sponsor: RedHill Biopharma Limited

Conditions Bronchiectasis Lung Diseases Pulmonary Mycobacterium Avium Complex Infection
Interventions Placebo RHB-204
Updated 13 times since 2020 Last updated: Mar 13, 2025 Started: Dec 1, 2020 Primary completion: Aug 28, 2023 Completion: Aug 28, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

extremely slow enrollment into study

Other terminated trials from RedHill Biopharma Limited

More terminations from RedHill Biopharma Limited

Listed as NCT04616924, this PHASE3 trial focuses on Bronchiectasis and Lung Diseases and remains terminated or withdrawn. Sponsored by RedHill Biopharma Limited, it has been updated 13 times since 2020, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Sep 2022 · 10 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Jul 2023 · 5 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Apr 2025 — Sep 2025 [monthly]

    Terminated PHASE3

    Status: Active Not Recruiting → Terminated

  3. Sep 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Jul 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

▶ Show 8 earlier versions

  1. Feb 2023 — Jul 2023 [monthly]

    Recruiting PHASE3

  2. Sep 2022 — Feb 2023 [monthly]

    Recruiting PHASE3

  3. Nov 2021 — Sep 2022 [monthly]

    Recruiting PHASE3

  4. Sep 2021 — Nov 2021 [monthly]

    Recruiting PHASE3

  5. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  6. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE3

  7. Jan 2021 — May 2021 [monthly]

    Recruiting PHASE3

  8. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • RedHill Biopharma Limited
Data source: RedHill Biopharma Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Boston, United States , Charleston, United States , Clearwater, United States , Farmington, United States , Gainesville, United States , Glendale, United States , Kansas City, United States , Margate, United States , New Orleans, United States and 14 more locations